OBJECTIVES: To describe patient reported outcomes (PROs) among those who have initiated targeted biologic treatment in a US observational cohort of patients with Rheumatoid Arthritis (RA). METHODS: Eligible patients were from the Corrona RA registry who had initiated a biologic agent between 2001-2016 and had a 6 month follow-up visit post initiation. Outcomes included the Clinical Disease Activity Index (CDAI), pain and fatigue (visual analog score; 0-100); morning stiffness (yes/no and hours); patient reported depression and anxiety; and others. Participants were grouped by initiation of a biologic: 1st line initiators, (patients initiating their 1st biologic), 2nd line initiators, and 3rd+ line initiators and by Tumor Necrosis Factor inhibitors (TNFi) and non-TNFi therapies. Means (SD) of outcomes are presented as changes between initiation and the 6 month follow-up visit by line of therapy. RESULTS: CONCLUSIONS: Despite many therapies to treat RA, patients still experience significant burden of disease. For the majority of outcomes, biologic naïve patients reported the largest improvements; lesser improvements occurred in 2nd and 3rd line initiators. Initiators of non-TNFi had more homogenous changes across lines of therapy.